The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Choosing Your MedsChoosing Your Meds
Rollover images to visit our other forums!
  • Email Email
  • Glossary Glossary

Mono/Duotherapy HAART
Mar 19, 2012

Hello Doctor- I have been HIV positive for ~ 2 years now, on Truvada with Isentress, VL is undetectable, CD4 count 680. I am very adherent with my meds, never miss any doses! When I started HAART, my CD4 count was 189, VL ~ 5 million (this was during acute infection as my HIV antibody was negative). My question is: at this point would it be safe & effective to drop to one or two meds instead of 3 to maintain viral suppression. As I said, I am very adherent. I just would like to use the LEAST amount of meds possible to maintain good viral suppression. How likely is it, that by just staying on Truvada for example, my VL will soar up? Thanks for advice.

Response from Dr. Young

Hello and thanks for posting.

Dual or single drug therapy is definitely not recommended, even after suppression with a three drug regimen, like Atripla. Indeed, this strategic question was asked in clinical trials in years past, with negative results.

I would not advise continuing on Truvada alone, you'd risk treatment failure and the development of drug resistance.


change of regimen (scheduled for tomorrow)
i miss a dose

  • Email Email
  • Glossary Glossary



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint